Published in Stroke on February 28, 2008
Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial. Crit Care (2015) 1.42
Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia. Curr Opin Nephrol Hypertens (2008) 0.95
Demographic and health factors associated with enrollment in posttrial studies: the Women's Health Initiative Hormone Therapy Trials. Clin Trials (2013) 0.86
Ordinal reanalysis of the SHEP trial. Stroke (2008) 0.78
Innovative collaborative practice to optimize pharmacotherapy for frail older patients. Can J Hosp Pharm (2014) 0.75
Optimal management of hypertension in elderly patients. Integr Blood Press Control (2010) 0.75
[Lipid lowering therapy in geriatric patients]. Z Gerontol Geriatr (2013) 0.75
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Weekend versus weekday admission and mortality from myocardial infarction. N Engl J Med (2007) 9.04
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 3.89
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med (2006) 2.81
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich) (2013) 2.64
Meta-analysis of statin effects in women versus men. J Am Coll Cardiol (2012) 2.56
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol (2005) 2.52
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation (2008) 2.51
Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med (2015) 2.42
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) (2005) 2.35
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J (2010) 2.32
The Society for Clinical Trials supports United States legislation mandating trials registration. Position paper. Clin Trials (2004) 2.21
Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA (2011) 2.21
Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation (2008) 2.06
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Comprehensive stroke centers overcome the weekend versus weekday gap in stroke treatment and mortality. Stroke (2011) 2.01
Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med (2005) 1.99
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation (2011) 1.97
Ethnic comparison of weight loss in the Trial of Nonpharmacologic Interventions in the Elderly. Obes Res (2002) 1.89
Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol (2007) 1.76
Low-fat dietary pattern and lipoprotein risk factors: the Women's Health Initiative Dietary Modification Trial. Am J Clin Nutr (2010) 1.73
Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis (2008) 1.68
Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Intern Med (2010) 1.64
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol (2012) 1.62
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes (2012) 1.59
Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. J Hypertens (2010) 1.55
The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med (2006) 1.53
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation (2002) 1.51
Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation (2004) 1.51
Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study. Circ Cardiovasc Qual Outcomes (2009) 1.48
Evening dosing of antihypertensive therapy to reduce cardiovascular events: a third type of evidence based on a systematic review and meta-analysis of randomized trials. J Clin Hypertens (Greenwich) (2014) 1.46
Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens (2002) 1.45
Visit-to-visit blood pressure variability and cardiovascular death in the Systolic Hypertension in the Elderly Program. J Clin Hypertens (Greenwich) (2013) 1.43
Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. J Hypertens (2014) 1.42
Has oseltamivir been shown to be effective for treatment of H5N1 influenza? J Infect Dis (2010) 1.41
Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol (2003) 1.39
Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. J Rheumatol (2008) 1.37
Trends in mortality of acute myocardial infarction after discharge from the hospital. Circ Cardiovasc Qual Outcomes (2010) 1.34
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. Am Heart J (2007) 1.33
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA (2008) 1.30
Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Gen Intern Med (2008) 1.28
The effectiveness of outpatient appointment reminder systems in reducing no-show rates. Am J Med (2010) 1.27
Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol (2009) 1.24
Trends in incidence and mortality rates of ventricular septal rupture during acute myocardial infarction. Am J Cardiol (2010) 1.22
The relationship between cognitive function and physical performance in older women: results from the women's health initiative memory study. J Gerontol A Biol Sci Med Sci (2009) 1.21
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) (2008) 1.21
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol (2007) 1.19
Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail (2006) 1.19
Triggering of transmural infarctions, but not nontransmural infarctions, by ambient fine particles. Environ Health Perspect (2010) 1.18
Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone. Curr Control Trials Cardiovasc Med (2002) 1.13
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenet Genomics (2008) 1.12
Effect of anemia on 1-year mortality in patients with acute myocardial infarction. Am Heart J (2002) 1.11
Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study. Clin Trials (2013) 1.11
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med (2008) 1.09
Treating hypertension in the very old. N Engl J Med (2008) 1.08
Survival Differences in Clinical Trials With Long-Term Follow-Up. J Am Coll Cardiol (2016) 1.07
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation (2002) 1.06
The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Arch Intern Med (2004) 1.06
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) (2011) 1.04
Risk factor clustering in the insulin resistance syndrome and its relationship to cardiovascular disease in postmenopausal white, black, hispanic, and Asian/Pacific Islander women. Metabolism (2003) 1.03
Cardiovascular manifestations of acute pancreatitis. J Crit Care (2010) 0.98
Refined ambient PM2.5 exposure surrogates and the risk of myocardial infarction. J Expo Sci Environ Epidemiol (2013) 0.97
Permanent pacing is a risk factor for the development of heart failure. Am J Cardiol (2005) 0.94
The triggering of myocardial infarction by fine particles is enhanced when particles are enriched in secondary species. Environ Sci Technol (2013) 0.93
Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab (2009) 0.93
Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) (2006) 0.92
Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol (2004) 0.92
Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT. Int J Hypertens (2013) 0.92
Cardiopulmonary bypass has a modest association with cancer progression: a retrospective cohort study. BMC Cancer (2013) 0.92
Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens (2004) 0.92